Physician profile
Daniela Rojas
NPI 1740840222
$3,891.15
in general payments reported to CMS, 2019-2025
31 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.01 · 2022: $273 · 2023: $1,347 · 2024: $1,211 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,592.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $761.32 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $396.35 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $369.09 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $268.90 | 2023-2025 | |
| Glaxosmithkline, LLC. | $261.27 | 2023-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Pfizer INC. | $226.72 | 2023-2025 | |
| Lilly USA, LLC | $190.52 | 2022-2025 | Mounjaro, Zepbound, Ebglyss |
| Idorsia Pharmaceuticals US INC | $137.84 | 2022-2024 | Quviviq |
| Antares Pharma, INC. | $135.26 | 2024-2025 | Xyosted |
| Sumitomo Pharma America, INC. | $116.31 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $97.88 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $95.64 | 2022-2025 | Farxiga |
| Heartflow, INC. | $90.07 | 2024 | |
| Sanofi-Aventis U.S. LLC | $86.67 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $80.74 | 2024-2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $75.63 | 2022-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Abbott Laboratories | $62.64 | 2025 | Freestyle Libre 3 |
| Halozyme INC | $60.69 | 2023 | |
| Dexcom, INC. | $56.94 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $50.52 | 2024-2025 | Repatha, Otezla, Otezla |
| Corcept Therapeutics | $47.63 | 2025 | Korlym |
| Amneal Pharmaceuticals LLC | $33.85 | 2023-2024 | Unithroid |
| Csl Behring | $26.01 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.98 | 2025 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $21.15 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.15 | 2024 | Xifaxan |
| Axsome Therapeutics, INC. | $20.74 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $20.46 | 2024 | Spravato |
| Dynavax Technologies Corporation | $19.83 | 2022 | |
| Organon LLC | $18.72 | 2024 | |
| Recordati_rare_diseases_inc. | $17.63 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.